晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展

Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in over...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411950/
https://www.ncbi.nlm.nih.gov/pubmed/36002199
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.23
_version_ 1784775381028438016
collection PubMed
description Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in overcoming this molecularly defined acquired resistance. Emerging data also demonstrate MET amplification as a resistance driver to TKIs-treated anaplastic lymphoma kinase (ALK)-, RET-, and ROS1-fusion NSCLC. Here, we review the literature on recent research progress of MET amplification as a resistance driver to targeted therapy in oncogene-driven NSCLC and summarize the progress of clinical strategies to overcome the resistance mechanism.
format Online
Article
Text
id pubmed-9411950
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-94119502022-09-12 晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展 Zhongguo Fei Ai Za Zhi 综述 Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in overcoming this molecularly defined acquired resistance. Emerging data also demonstrate MET amplification as a resistance driver to TKIs-treated anaplastic lymphoma kinase (ALK)-, RET-, and ROS1-fusion NSCLC. Here, we review the literature on recent research progress of MET amplification as a resistance driver to targeted therapy in oncogene-driven NSCLC and summarize the progress of clinical strategies to overcome the resistance mechanism. 中国肺癌杂志编辑部 2022-08-20 /pmc/articles/PMC9411950/ /pubmed/36002199 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.23 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展
title 晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展
title_full 晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展
title_fullStr 晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展
title_full_unstemmed 晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展
title_short 晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展
title_sort 晚期非小细胞肺癌met扩增介导获得性耐药的研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411950/
https://www.ncbi.nlm.nih.gov/pubmed/36002199
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.23
work_keys_str_mv AT wǎnqīfēixiǎoxìbāofèiáimetkuòzēngjièdǎohuòdéxìngnàiyàodeyánjiūjìnzhǎn
AT wǎnqīfēixiǎoxìbāofèiáimetkuòzēngjièdǎohuòdéxìngnàiyàodeyánjiūjìnzhǎn
AT wǎnqīfēixiǎoxìbāofèiáimetkuòzēngjièdǎohuòdéxìngnàiyàodeyánjiūjìnzhǎn

Ejemplares similares